Why the study?
Does endocavitary fulguration prevent recurrent ventricular tachycardia in patients with high-risk, drug-resistant VT?
Population
26 patients with high-risk ventricular tachycardia resistant to antiarrhythmics. Etiologies included…
Design
Case_series
Follow-up
average nearly two years (range 15 to 34 months)
Authors
Loading...
May support fulguration in select refractory VT cases; leaves open need for prospective trials before broader adoption.
Does endocavitary fulguration prevent recurrent ventricular tachycardia in patients with high-risk, drug-resistant VT?
Endocavitary fulguration is an effective treatment for high-risk, drug-resistant ventricular tachycardia, achieving a 90% success rate, though early procedural mortality is a notable risk.
Fontaine et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: